Spero Therapeutics Inc (SPRO) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Spero Therapeutics, Inc. (SPRO) - corporate logo

The development of antibiotics to combat resistant bacteria provides Spero Therapeutics (SPRO) with long-term revenue through patent protection. The market dynamics of the asset with the 3.89 indicator visualize this process. Spero Therapeutics (SPRO) automates drug creation via algorithms, although final tests remain with humans. The business relies on a sovereign cycle, making it independent of the global economy and a reliable defensive asset.

Spero Therapeutics Inc - SPRO Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/11/2026)

Summary analytical data breakdowns for sperotherapeutics.com (SPRO)

- current price and projected stock value:
Stock Price Spero|SPRO - Analyst Median Target
- market capitalization details:
Market Value Spero Pharma|SPRO - Business Value
- book value of equity indicators:
Book Value per Share Spero Therapeutics|SPRO - Net Asset Value|Market Capitalization to Book Value Ratio sperotherapeutics.com|SPRO - Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Spero Therapeutics|SPRO - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Spero Therapeutics, Inc.|SPRO - Company Cumulative Indebtedness|Debts to Book Capitalization Spero Pharma|SPRO - Long-Term Debt Volume|Company Short-Term Debt Spero Therapeutics|Quick Liquidity sperotherapeutics.com
- financial results and valuation multiples details:
SPRO - Company Profit|Expected Profit Spero Therapeutics|SPRO - Business Payback Period|Future Price to Earnings Spero Therapeutics|SPRO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Spero Pharma|SPRO - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Spero Therapeutics|SPRO - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months sperotherapeutics.com|SPRO - Earnings per share increase in current year|Net earnings per share growth forecast for next year Spero Therapeutics
General company analysis:Spero SPRO
Product sample of Spero Therapeutics Inc

A conservative investor assesses the stability of Spero Therapeutics (SPRO) through the lens of total assets and liabilities relative to operating profit. When analyzing the Enterprise Value to EBITDA chart, it is essential to understand that this metric compares the total business price with its ability to generate cash flow from the sale of innovative antibiotics, determining investment attractiveness amid a high debt load.

Analysis of competing companies

EV/EBITDA Multiple SMMT (Summit Therapeutics Inc)|Total Company Value to Operating Income Before Depreciation Ratio Moderna Therapeutics (MRNA)|PCVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TARS (tarsusrx.com) - Enterprise Value to Operating Income Before Depreciation|CRMD: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio MCRB (Seres Therapeutics Inc.)|SCYX (SCYNEXIS Inc) - EV/EBITDA Multiple|Company Value to EBITDA AN2 Bio ANTX|EV/EBITDA Multiple PYPD|Enterprise Value to EBITDA Ratio ysbiopharm.com LSB|Iterum Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio PHGE (BiomX Inc)|BioPharma Bio - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio 60 Degrees Pharmaceuticals SXTP|Oragenics, Inc. (OGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA opgen.com (OPGN)